AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05085106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eye drop
Description: Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
Study NCT01258075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose colesevelam
Description: 3.75 grams colesevelam hydrochloride in oral suspension
Study NCT01258075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose colesevelam
Description: 0.625 grams colesevelam hydrochloride in oral suspension
Study NCT03738800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 Cream 200 µg/g
Description: A fixed dose (determined at Visit 1) of 200 µg/g applied topically twice weekly to up to 90% BSA
Study NCT03738800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 Cream 100 µg/g
Description: A fixed dose (determined at Visit 1) of 100 µg/g applied topically twice weekly to up to 90% BSA
Study NCT03738800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD5789 Cream Vehicle
Description: A fixed dose (determined at Visit 1) applied topically twice weekly, up to 36 g per dose up to 90% BSA
Study NCT04428203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex Oral Liquid Product
Description: patients with rising PSA after failure of localized therapy will receive Epidiolex PO once daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients receive an Epidiolex taper for 7-10 days after withdrawing from study for any reason or completion of the study period.
Study NCT01194934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: 4 mg/kg daily IV for 5 days
Study NCT01194934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: 2 mg/kg daily IV for 5 days
Study NCT01194934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: 5 µg/kg SC daily for 5 days
Study NCT01194934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12 in combination with Filgrastim
Description: Safe and efficacious dose regimen according to results of groups A and B
Study NCT02359799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntelliStretch
Description: The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.
Study NCT02918552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
Study NCT02918552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
Study NCT02758444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient Powder (MNP) + 15 mg Zn
Description: Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.
Study NCT02758444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNP + 10 mg Zn
Description: Same as above except MNP will contain 10 mg Zn
Study NCT02758444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNP + 5 mg Zn
Description: Same as above except MNP will contain 5 mg Zn
Study NCT02758444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MNP without Zn
Description: Same as above except MNP will not contain Zn
Study NCT05597579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DAPAR Tests (IQ equivalent test)
Description: This study will compare DAPAR scores before and after the onset of the psychotic illness.
Study NCT00438802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
Study NCT03535051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser
Description: Monthly fractional carbon dioxide laser sessions
Study NCT03535051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Oint 0.03%
Description: topical daily tacrolimus ointment application
Study NCT03535051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Oint 0.03%
Description: topical daily tacrolimus ointment application
Study NCT01245868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Study NCT01245868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Study NCT01245868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Study NCT03978026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Each participant is compared to himself in 4 conditions,
Study NCT03978026 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nap
Description: Each participant is compared to himself in 4 conditions,
Study NCT02438150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital fire video training
Description: Participants will watch a video about hospital fire training which last for 30 minutes
Study NCT02438150 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non hospital fire video training
Description: Participants will watch a video about volcanic eruption which last for 30 minutes
Study NCT03892369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Ethanol administration
Study NCT03897205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: Imlifidase is an immunoglobulin G (IgG) degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.
Study NCT03897205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins and then the plasma is passed back to the subject.
Study NCT00637325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
Study NCT04981184 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gait and balance measurement
Description: Virtual gait training procedures are included. Balance training procedures with Biodex Balance system are included too.
Study NCT01878136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
Study NCT01878136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
Study NCT03371706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Bridge™
Description: Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
Study NCT03371706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-Based Impairment Focused
Description: Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
Study NCT01239537 — intervention group
Intervention type: DRUG
Intervention: Seasonal Flu vaccine
Description: 1 dose of seasonal trivalent flu vaccine (Fluarix)
Study NCT01193023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Support
Description: Ventilation under pressure support
Study NCT01193023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: Ventilation under NAVA
Study NCT04389918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tality
Description: Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.
Study NCT00874484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clexane (enoxaparin)
Description: One arm receives enoxoparin, second arm receives saline
Study NCT00874484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clexane (enoxaparin)
Description: One arm receives enoxoparin, second arm receives saline
Study NCT00569036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
Study NCT00339196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 azacytidine - VALPROIC acid- Retinoic acid
Description: 5 azacytidine - VALPROIC acid- Retinoic acid
Study NCT00310466 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual immunotherapy
Description: once daily intake of sublingual drops
Study NCT00310466 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily intake of sublingual drops
Study NCT02898558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnification hand size
Description: Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.
Study NCT02898558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnifying lenses
Study NCT01643733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using Flow measurements to guide fistula angioplasty (Transonics)
Description: Transonics flow measurements in the fistula would be used to guide the fistula intervention
Study NCT03652116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration by Bupivacaine
Description: Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
Study NCT03652116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration by Pethidine
Description: Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
Study NCT00508937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: 15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
Study NCT00508937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
Study NCT00508937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
Study NCT00508937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
Study NCT00508937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
Study NCT02722837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily
Study NCT03526926 — intervention group
Intervention type: DRUG
Intervention: CPX-351
Description: VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.
Study NCT02252471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choices-Teen
Description: Choices-Teen participants in this condition will receive two brief motivational-interviewing-based counseling sessions, and one counseling session with a physician.
Study NCT03647605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Mind
Description: Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: Public Speaking in Lecture Hall and Telephoning in Public. Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes.
Study NCT00743938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-690514
Description: Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity
Study NCT00743938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity
Study NCT01143064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
Study NCT01143064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid emulsion without progesterone
Description: Intravenous administration equal to 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
Study NCT02638259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP2015
Description: Enbrel comparator
Study NCT02638259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP2015
Description: Enbrel comparator
Study NCT02607306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
Study NCT02607306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
Study NCT02607306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
Study NCT02951039 — intervention group
Intervention type: DRUG
Intervention: Edoxaban
Description: Prescribed according to approved label
Study NCT03362138 — intervention group
Intervention type: DEVICE
Intervention: dermoscopy
Description: Solely after the dermatologist has decided to biopsy a lesion and sent the patient to biopsy, a dermoscopic image is captured by a camera attached to a dermoscope.
Study NCT00628095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-224,535
Description: 500 mg po BID
Study NCT00628095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active ingredient
Study NCT05362240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Four corner fusion
Description: First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denuded the articulating surfaces between lunate , capitate , hamate and triquetrum . Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones
Study NCT05362240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three corner fusion without triquetrum excision
Description: First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denude the articulating surfaces between lunate , capitate , hamate and don not include triquetrum. Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones.
Study NCT01570569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
Study NCT01570569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
Study NCT01570569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
Study NCT01570569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocktail
Description: Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.~Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
Study NCT01570569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
Study NCT01570569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
Study NCT02061683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Description: Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
Study NCT03375515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes.
Study NCT03375515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes.
Study NCT03375515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCA pump
Description: 1. For opioid-intolerant patients: initial dose 0.5 mg intravenous hydromorphone.~2. For opioid-tolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs.
Study NCT01658449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalable Hypertonic saline 7% + Hyaluronan 0.1%
Description: Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
Study NCT01658449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalable Hypertonic saline 7%
Description: Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
Study NCT00775554 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound guided hematoma block
Description: pt. will receive ultrasound guided hematoma block
Study NCT00775554 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound guided hematoma block
Description: ultrasound will be used to guide hematoma blocks
Study NCT02235441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test (CPET)
Description: All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.